Abstract
Immunotherapy with rIL-2 currently represents one of the most interesting therapeutic approaches to tumors. Ten patients with advanced phase neoplasms (3 melanomas and 7 renal) were admitted to the study. The subcutaneous treatment regime with rIL-2 (Proleukin-Cetus). The aim of the study is to monitor the peripheral immunological modifications induced by rIL-2 treatments and to detect eventual parameters correlated with clinical response. Preliminary analysis of our data demonstrate: subcutaneous administration of rIL-2 is able to induce an important immunological stimulation in all patients treated; nevertheless there seems not to be correlation between immunological parameters considered and the patients clinical response.
| Translated title of the contribution | Interleukin-2: Biological characteristics and therapeutic potential in oncology |
|---|---|
| Original language | Italian |
| Pages (from-to) | 21-26 |
| Number of pages | 6 |
| Journal | Folia Oncologica |
| Volume | 15 |
| Issue number | 1 |
| Publication status | Published - 1992 |
ASJC Scopus subject areas
- Oncology